HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Lazard Capital Markets 8th Annual Healthcare Conference on Tuesday, November 15, 2011 at 10:30 a.m. Eastern Time at the Pierre Hotel in New York, NY.
A live audio webcast of the presentation can be accessed under “Investor Events” in the Investor section of the Acorda website at www.acorda.com, or you may use the link: http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=194451&eventID=4239881
Please log in approximately 5 minutes before the scheduled time of the presentation to ensure a timely connection. An archived version of the webcast will be available until December 15, 2011 on the Investors section of www.acorda.com.
About Acorda
Therapeutics
Acorda Therapeutics is a biotechnology company
developing therapies for multiple sclerosis, spinal cord injury and
related nervous system disorders. The Company is commercializing and
marketing AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, in the United
States. AMPYRA is a potassium channel blocker approved as a treatment to
improve walking in patients with multiple sclerosis (MS); this was
demonstrated by an improvement in walking speed. AMPYRA was developed
using Alkermes’ Matrix Drug Absorption System (MXDAS®)
technology and is manufactured by Alkermes Pharma Ireland Limited, a
subsidiary of Alkermes plc, based on a supply agreement with Acorda.
Acorda also markets ZANAFLEX CAPSULES® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
Forward-Looking Statements
This press release includes
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. All statements, other than statements of
historical facts, regarding management's expectations, beliefs, goals,
plans or prospects should be considered forward-looking. These
statements are subject to risks and uncertainties that could cause
actual results to differ materially, including Acorda Therapeutics'
ability to successfully market and sell Ampyra in the United States;
third party payors (including governmental agencies) may not reimburse
for the use of Ampyra at acceptable rates or at all and may impose
restrictive prior authorization requirements that limit or block
prescriptions; the risk of unfavorable results from future studies of
Ampyra; the occurrence of adverse safety events with our products;
delays in obtaining or failure to obtain regulatory approval of Ampyra
outside of the United States and our dependence on our collaboration
partner Biogen Idec in connection therewith; competition, including the
impact of anticipated potential generic competition on Zanaflex Capsules
revenues; failure to protect Acorda Therapeutics’ intellectual property,
to defend against the intellectual property claims of others or to
obtain third party intellectual property licenses needed for the
commercialization of our products; the ability to obtain additional
financing to support Acorda Therapeutics' operations; and, unfavorable
results from our research and development programs. These and other
risks are described in greater detail in Acorda Therapeutics' filings
with the Securities and Exchange Commission. Acorda Therapeutics may not
actually achieve the goals or plans described in its forward-looking
statements, and investors should not place undue reliance on these
statements. Forward-looking statements made in this release are made
only as of the date hereof, and Acorda Therapeutics disclaims any intent
or obligation to update any forward-looking statements as a result of
developments occurring after the date of this press release.